Your browser is no longer supported. Please, upgrade your browser.
Settings
VKTX Viking Therapeutics, Inc. daily Stock Chart
VKTX [NASD]
Viking Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.65 Insider Own3.10% Shs Outstand51.92M Perf Week15.78%
Market Cap270.50M Forward P/E- EPS next Y-0.50 Insider Trans0.00% Shs Float40.37M Perf Month14.51%
Income-18.90M PEG- EPS next Q-0.14 Inst Own40.60% Short Float7.22% Perf Quarter-15.70%
Sales- P/S- EPS this Y12.50% Inst Trans118.18% Short Ratio2.87 Perf Half Y100.38%
Book/sh1.60 P/B3.26 EPS next Y-8.30% ROA-59.40% Target Price9.13 Perf Year327.05%
Cash/sh1.49 P/C3.49 EPS next 5Y40.00% ROE-79.70% 52W Range0.88 - 7.36 Perf YTD28.33%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-29.18% Beta-
Dividend %- Quick Ratio12.40 Sales past 5Y- Gross Margin- 52W Low492.05% ATR0.37
Employees4 Current Ratio12.40 Sales Q/Q- Oper. Margin- RSI (14)62.01 Volatility8.15% 8.08%
OptionableYes Debt/Eq0.05 EPS Q/Q66.40% Profit Margin- Rel Volume1.20 Prev Close5.31
ShortableYes LT Debt/Eq0.00 EarningsMay 09 AMC Payout- Avg Volume1.01M Price5.21
Recom1.80 SMA2019.41% SMA5010.73% SMA20044.37% Volume1,211,929 Change-1.88%
Mar-26-18Resumed H.C. Wainwright Buy $11
Nov-28-17Reiterated Maxim Group Buy $5 → $8
Nov-21-17Initiated ROTH Capital Buy
Nov-10-17Resumed H.C. Wainwright Buy $7
Jul-17-17Reiterated H.C. Wainwright Buy $5 → $7
Aug-11-16Reiterated Laidlaw Buy $20 → $10
May-24-16Initiated Maxim Group Buy $5
Apr-07-16Initiated H.C. Wainwright Buy $6
May-14-18 11:30AM  VKTX: Enrollment of Phase 2 Trial of VK2809 Nearing Completion Zacks Small Cap Research
May-09-18 04:05PM  Viking Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update PR Newswire
May-04-18 08:00AM  2 Cheap Growth Stocks to Buy Right Now Motley Fool
May-02-18 07:30AM  Viking Therapeutics to Report Financial Results for First Quarter 2018 on May 9, 2018 PR Newswire +5.20%
Apr-30-18 04:07PM  William Blair Initiates Viking With An Outperform Rating After Competitor Proves Strategy Benzinga
Apr-19-18 07:55AM  Report: Developing Opportunities within Canada Goose, Viking Therapeutics, Vector Group, Bruker, Air Transport Services Group, and Raymond James Financial Future Expectations, Projections Moving into 2018 GlobeNewswire
Apr-13-18 11:19AM  What Should Investors Know About Viking Therapeutics Incs (NASDAQ:VKTX) Future? Simply Wall St.
Apr-12-18 08:00AM  Why Viking Therapeutics, Inc. Stock Cratered in March Motley Fool +5.20%
Mar-09-18 10:15AM  VKTX: Data from Phase 2 Study of VK2809 in NASH in 2H18; Sufficient Cash to Fund Operations to 2020 Zacks Small Cap Research
Mar-08-18 12:45PM  Here's Why Viking Therapeutics Stock Dropped as Much as 17.3% Today Motley Fool -6.17%
Mar-07-18 04:05PM  Viking Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update PR Newswire
12:15PM  Viking Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-06-18 07:00AM  Viking Therapeutics to Present at Upcoming Investor Conferences PR Newswire -5.61%
Feb-28-18 11:33AM  Penny Stocks to Watch for March 2018 Investopedia
07:00AM  Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2017 on March 7, 2018 PR Newswire
Feb-09-18 07:50AM  Report: Exploring Fundamental Drivers Behind Great Lakes Dredge & Dock, American Midstream Partners, LP, BioDelivery Sciences International, Viking Therapeutics, Pattern Energy Group, and Computer Programs and Systems New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Feb-08-18 04:22PM  Who Are The Major Shareholders In Viking Therapeutics Inc (NASDAQ:VKTX)? Simply Wall St. -8.51%
07:30AM  Biotricity (BTCY) Poised for Breakout with New FDA Clearance: +100% Back To Highs? ACCESSWIRE
Feb-07-18 07:05AM  Viking Therapeutics to Present at 2018 BIO CEO & Investor Conference PR Newswire +16.08%
Feb-06-18 04:05PM  Viking Therapeutics Announces Closing of Public Offering of Common Stock PR Newswire -5.39%
Feb-02-18 03:50PM  Viking Therapeutics Inc Now Has Cash Runway to Hit Multiple Catalysts Through 2020; Jason McCarthy Chimes in SmarterAnalyst +14.31%
08:33AM  Viking Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock PR Newswire
Feb-01-18 04:01PM  Viking Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
02:49PM  Should You Be Concerned About Viking Therapeutics Incs (NASDAQ:VKTX) Risks? Simply Wall St.
Jan-30-18 03:27PM  Biotech Viking Therapeutics Could Double From Here -- But Not Without Risk TheStreet.com -8.93%
Jan-24-18 12:00PM  VKTX: Positive Results for MGL-3196 Increases Our Confidence for Success of VK2809 Phase 2 Trial Zacks Small Cap Research
Jan-02-18 07:05AM  Viking Therapeutics to Present at Biotech Showcase 2018 PR Newswire +10.34%
Dec-29-17 05:05PM  What Should We Expect From Viking Therapeutics Incs (NASDAQ:VKTX) Earnings Over The Next Few Years? Simply Wall St.
Dec-11-17 04:15PM  Viking Therapeutics Announces Closing of Public Offering of Common Stock PR Newswire
Dec-08-17 01:59PM  5 Cheap Biotech Stocks to Snag on the Bounce InvestorPlace +10.27%
Dec-06-17 08:08PM  Viking Therapeutics Announces Pricing of $12.8 Million Public Offering of Common Stock PR Newswire +9.12%
Dec-05-17 04:18PM  Viking Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
Nov-30-17 07:40AM  Blog Exposure - Viking Therapeutics Reports Positive Top-Line Results from Phase-2 Study of VK5211 in Patients Recovering from Hip Fracture ACCESSWIRE +12.59%
Nov-28-17 04:00PM  VKTX: Positive Results From Phase 2 Study of VK5211 in Hip Fracture Zacks Small Cap Research -6.62%
07:44AM  Viking Therapeutics stock surges 18% premarket on positive trial of hip fracture treatment MarketWatch
07:02AM  Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture PR Newswire
Nov-20-17 08:20AM  Investor Expectations to Drive Momentum within Vector Group, NovoCure, ORBCOMM, Ecolab, Bank of America, and Viking Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
Nov-09-17 02:30PM  VKTX: Data From Phase 2 Trial of VK5211 to be Reported Soon Zacks Small Cap Research
Nov-08-17 04:05PM  Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update PR Newswire -6.93%
Nov-01-17 07:30AM  Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017 PR Newswire
Oct-31-17 08:00AM  Viking Therapeutics, Positive Clinical Data Across the Pipeline, Analysts Target ACCESSWIRE
Oct-26-17 01:00PM  VKTX: Poster Presentations on VK2809 and VK0214 Highlight Positive Preclinical Data for Both Compounds Zacks Small Cap Research -6.52%
07:20AM  Featured Company News - Viking Presents Positive Results From In Vivo Study of VK2809 in NASH at the Annual Meeting of AASLD ACCESSWIRE
Oct-24-17 07:05AM  Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) PR Newswire -5.36%
Oct-23-17 07:05AM  Viking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 87th Annual Meeting of the American Thyroid Association PR Newswire -6.67%
Oct-11-17 11:30AM  VKTX: KOLs Highlight Necessity For Effective Hip Fracture Treatment Zacks Small Cap Research
Oct-04-17 07:05AM  Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) PR Newswire +8.62%
Oct-02-17 07:20AM  Corporate News Blog - Viking Enters into Purchase Agreements worth $16.25 Million with Lincoln Park Capital ACCESSWIRE
Sep-29-17 07:05AM  Viking Therapeutics Announces Purchase Agreements for up to $16.25 Million with Lincoln Park Capital PR Newswire +6.11%
Sep-25-17 07:30AM  Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settings PR Newswire +5.04%
Sep-21-17 06:21PM  Should You Buy Viking Therapeutics Inc (VKTX) Now? Simply Wall St.
Sep-12-17 11:00AM  VKTX: Encouraging In Vivo Data For VK2809 From Mouse Model of GSD 1a and Gene Expression Analysis in Mouse Model of NASH Zacks Small Cap Research +8.62%
Sep-11-17 07:05AM  Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH) PR Newswire
Sep-07-17 07:02AM  Viking Therapeutics Announces Presentation of Data from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) at the 13th International Congress of Inborn Errors of Metabolism (ICIEM) PR Newswire +6.67%
Sep-05-17 07:30AM  Viking Therapeutics to Present at Rodman & Renshaw's 19th Annual Global Investment Conference PR Newswire
Aug-14-17 04:00PM  VKTX: Data From Phase 2 Trial of VK5211 Expected in 4Q17 Zacks Small Cap Research
Aug-09-17 04:05PM  Viking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
Aug-02-17 07:30AM  Viking Therapeutics to Report Financial Results for Second Quarter 2017 After Market Close on August 9, 2017 PR Newswire -9.71%
Jul-14-17 07:20AM  Corporate News Blog - Viking Therapeutics Completes Enrollment in Phase-2 study of VK5211 in Patients Recovering from Hip Fracture Accesswire
Jul-12-17 07:00AM  Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture PR Newswire
Jul-06-17 08:00AM  Viking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors PR Newswire
Jun-19-17 11:00AM  VKTX Raises $4.3 Million in Gross Proceeds From Registered Direct Offering Zacks Small Cap Research
Jun-14-17 09:55AM  Viking Therapeutics Announces $4.3 Million Registered Direct Offering PR Newswire -11.11%
Jun-08-17 08:15AM  Featured Company News - Viking Therapeutics' VK2809 Shows Encouraging Results in Non-Alcoholic Steatohepatitis Accesswire
Jun-07-17 01:00PM  VKTX: Potential of VK2809 in NASH Treatment Shown in Diet-Induced Mouse Model Zacks Small Cap Research
Jun-06-17 07:14AM  Viking Therapeutics Announces Promising Top Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH) PR Newswire
May-31-17 07:30AM  Viking Therapeutics to Present at Upcoming Investor Conferences PR Newswire
May-12-17 04:00PM  VKTX: Multiple Data Readouts Ahead in 2017 Zacks Small Cap Research -6.87%
May-10-17 04:05PM  Viking Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
May-03-17 07:30AM  Viking Therapeutics to Report Financial Results for First Quarter 2017 After Market Close on May 10, 2017 PR Newswire
Mar-28-17 07:30AM  Viking Therapeutics to Present at H.C. Wainwright & Co.'s 1st Annual NASH Investor Conference PR Newswire +8.20%
Mar-25-17 01:04PM  VIKING THERAPEUTICS, INC. Financials
Mar-24-17 11:45AM  VKTX: Results from Phase 2 Trial of VK5211 in Hip Fracture in mid-2017
Mar-21-17 04:16PM  VIKING THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:05PM  Viking Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update PR Newswire
07:07AM  Q4 2016 Viking Therapeutics Inc Earnings Release - After Market Close
Mar-02-17 07:30AM  Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2016 After Market Close on March 21, 2017 PR Newswire -5.23%
Feb-28-17 07:30AM  Viking Therapeutics to Present at Upcoming Investor Conferences PR Newswire
Feb-15-17 01:00PM  VKTX: Successful Preclinical Data for VK2809 in Glycogen Storage Disease 1a Zacks Small Cap Research +6.16%
Feb-14-17 06:25PM  VIKING THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity
07:05AM  Viking Therapeutics and PoC Capital Enter Agreement to Fund Clinical Development of VK2809 in Glycogen Storage Disease Ia (GSD Ia) PR Newswire
Feb-09-17 07:03AM  Viking Therapeutics Announces Initial Results from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) PR Newswire -5.37%
Feb-07-17 07:30AM  Viking Therapeutics to Present at 2017 BIO CEO & Investor Conference PR Newswire +7.24%
Jan-05-17 04:48PM  Viking Therapeutics Announces Senior Level Appointments to Management Team PR Newswire
Dec-21-16 07:30AM  Viking Therapeutics to Present at Biotech Showcase 2017 PR Newswire -7.96%
Dec-06-16 04:05PM  Viking Therapeutics Receives Orphan Drug Designation for VK0214 from the U.S. Food and Drug Administration for the Treatment of X-Linked Adrenoleukodystrophy PR Newswire +10.00%
Nov-29-16 07:30AM  Viking Therapeutics to Present at the LD Micro Main Event PR Newswire
Nov-16-16 08:15AM  Blog Coverage Viking Presents New Clinical Data on VK2809 Accesswire
Nov-15-16 11:00AM  VKTX: Additional Data Show Promise of VK2809 in Lipid Disorders
07:02AM  Viking Therapeutics Presents New Clinical Data on VK2809 in Subjects with Elevated Cholesterol at American Heart Association Scientific Sessions 2016 PR Newswire
Nov-10-16 04:17PM  VIKING THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and +16.00%
04:05PM  Viking Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update PR Newswire
07:07AM  Q3 2016 Viking Therapeutics Inc Earnings Release - After Market Close
Nov-03-16 07:30AM  Viking Therapeutics to Host Conference Call to Discuss Third Quarter 2016 Financial Results PR Newswire -9.14%
Oct-13-16 07:30AM  Viking Therapeutics to Present at the 2016 BIO Investor Forum PR Newswire
Oct-04-16 07:16AM  VIKING THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
07:05AM  Viking Therapeutics Doses First Patient in Phase 2 Clinical Trial of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease PR Newswire
Sep-28-16 07:02AM  7 Stocks Under $10 That Could Make You a Lot of Money
Sep-27-16 12:30PM  VKTX: Encouraging Preclinical Data for VK0214 in Mouse Model of X-ALD
Sep-26-16 07:05AM  Viking Therapeutics Presents Positive Proof-of-Concept Data for VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 86th Annual Meeting of the American Thyroid Association PR Newswire
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.